Black Diamond Therapeutics, Inc.
An oncology drug developer, Black Diamond Therapeutics makes small-molecule medicines that treat whole 'families' of cancer-causing mutations with a single therapy, rather than one mutation at a time. Its lead experimental drug, BDTX-1535, can cross the blood-brain barrier to reach hard-to-treat brain tumors like glioblastoma. Co-founded in 2016 by scientists David Epstein and Elizabeth Buck, the company began as ASET Therapeutics before taking the Black Diamond name — a rebrand with no public origin story.
Sold 221.6K
Granted 61.8K
Bought 400.0K · Sold 5.78M
Granted 75.0K
Granted 80.2K
Granted 75.0K
Granted 75.0K
Granted 75.0K
Granted 45.0K
Granted 10.3K
Granted 8.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Versant Vantage I, L.P. +3 co-filers10% owner · 1 transaction | — | 6.21Mas of Aug 2024 | — | — | 221.6K |
| Behbahani AliDirector · 12 transactions | +30.4% | 4.55M | 61.8K | — | — |
| BB Biotech Ag +1 co-filer10% owner · 8 transactions | -60.2% | 3.23Mas of Mar 2025 | — | 400.0K | 5.78M |
| Buck ElizabethCHIEF SCIENTIFIC OFFICER · 1 transaction | +78.8% | 170.2Kas of Jan 2025 | 75.0K | — | — |
| Velleca Mark A.PRESIDENT & CEO, Director · 2 transactions | +194.1% | 121.5Kas of Jan 2025 | 80.2K | — | — |
| Jones ErikaSEE REMARKS · 1 transaction | +738.9% | 85.2Kas of Jan 2025 | 75.0K | — | — |
| Hatzis-Schoch BrentSEE REMARKS · 1 transaction | +892.9% | 83.4Kas of Jan 2025 | 75.0K | — | — |
| Yurasov SergeyCHIEF MEDICAL OFFICER · 1 transaction | — | 75.0Kas of Jan 2025 | 75.0K | — | — |
| Raman PrakashDirector · 9 transactions | — | 45.0K | 45.0K | — | — |
| Dixon Wendy LDirector · 3 transactions | +37% | 38.1Kas of Mar 2024 | 10.3K | — | — |
| Campbell ShannonDirector · 3 transactions | — | 8.9Kas of Dec 2024 | 8.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -5.61M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.